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Abstract
The central event in Protein Misfolding Disorders (PMDs) is the accumulation of a misfolded
form of a naturally expressed protein. Despite the diversity of clinical symptoms associated to
different PMDs, many similarities in their mechanism suggest that distinct pathologies may cross-
talk at the molecular level. The main goal of this study was to analyze the interaction of the
protein misfolding processes implicated in Alzheimer’s and prion diseases. For this purpose we
inoculated prions in an Alzheimer’s transgenic mouse model that develop typical amyloid plaques
and followed the progression of pathological changes over time. Our findings show a dramatic
acceleration and exacerbation of both pathologies. The onset of prion disease symptoms in
transgenic mice appeared significantly faster with a concomitant increase on the level of misfolded
prion protein in the brain. A striking increase in amyloid plaque deposition was observed in prion
infected mice compared with their non-inoculated counterparts. Histological and biochemical
studies showed the association of the two misfolded proteins in the brain and in vitro experiments
showed that protein misfolding can be enhanced by a cross-seeding mechanism. These results
suggest a profound interaction between Alzheimer’s and prion pathologies, indicating that one
protein misfolding process may be an important risk factor for the development of a second one.
Our findings may have important implications to understand the origin and progression of PMDs.
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Introduction
Misfolding and aggregation of proteins is the central pathogenic event in Protein Misfolding
Disorders (PMDs), which include Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), Huntington’s disease, diabetes type-2, systemic
amyloidosis and Transmissible Spongiform Encephalopaties (TSEs), among others (Chiti
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and Dobson, 2006; Soto, 2001). The main structural changes in the protein include an
increase of the β-sheet structure, oligomerization and formation of fibrillar amyloid-like
polymers (Nelson and Eisenberg, 2006). As a result, protein aggregates become insoluble,
resistant to proteolysis, and resilient to cellular clearance mechanisms. PMDs share some
common features such as their appearance late in life, the progressive and chronic nature of
the disease and the tissue deposition of misfolded protein aggregates. The misfolding and
aggregation mechanisms and its structural intermediates are very similar in all PMDs
(Glabe, 2006; Soto et al., 2006). The mechanism of aggregation follows a seeding-
nucleation process, in which the critical step is the generation of a misfolded seed that act as
a nucleus to catalyze further aggregation, leading to the formation of oligomeric and fibrillar
species (Soto et al., 2006).
TSEs or prion disorders affect humans and several animal species and are the only PMD
described as transmissible so far. In spite of their low incidence, TSEs have produced big
health and economic problems due to the Bovine Spongiform Encephalopathy epidemic and
the emergence of the new variant form of Creutzfeldt Jakob disease (CJD) in humans
(Bradley and Liberski, 2004). Compelling evidence indicates that the infectious agent in
TSEs is composed exclusively by the misfolded and aggregated prion protein (termed
PrPSc), which transmit the disease by inducing the auto-catalytic transformation of
thenormal host prion protein (termed PrPC) (Prusiner, 2004).
AD is characterized by the extracellular deposition of the Aβ peptide and intracellular
accumulation of hyperphosphorilated tau protein, both leading to synaptic dysfunction and
neuronal death (Cummings, 2004). Extensive biochemical, neuropathological and genetic
evidences suggest that the cerebral accumulation of misfolded Aβ is the central event in the
pathogenesis (Selkoe, 2000).
The co-existence of various misfolded aggregates has been described in vivo for several
proteins such as α-synuclein, tau, prion protein and Aβ, among others (for references, see
Giasson et al., 2003). Specifically, the co-existence of PrPSc and Aβ in patients with clinical
manifestation of both AD and TSE has been extensively reported (Haraguchi et al., 2009;
Muramoto et al., 1992; Tsuchiya et al., 2004; Yoshida et al., 2009). PrP has been identified
in senile plaques of AD patients and Aβ aggregates have been found within PrP deposits in
patients affected with CJD or Gertsmann-Straussler-Scheinker syndrome (Bugiani et al.,
1993; Hainfellner et al., 1998). Furthermore, in a study of patients with early-onset familial
AD it was found that all patients exhibited neuropathological characteristics of TSEs,
including spongiform degeneration and PrP accumulation in addition of the typical AD
alterations (Leuba et al., 2000). Finally, it was reported that the incidence of CJD in
inherited AD patients is way higher than the prevalence of the disease in the general
population (Masters et al., 1981). These findings suggest a strong interaction between TSE
and AD.
In spite the reported co-occurrence of AD and TSEs in patients, it is unclear whether both
pathologies interact or are simply co-existing. In the present study we aimed to evaluate the
interaction between AD and TSEs using mice models for both diseases.
Materials and Methods
Animal bioassays
For these studies we used the well-characterized Tg2576 transgenic mice model of AD that
overexpresses the human amyloid precursor protein bearing the Swedish mutation (Hsiao et
al., 1996). Groups of 365 and 45 days old Tg2576 mice were intra-peritoneally (i.p.)
inoculated with 50 μL of PBS or 1.5% brain homogenate prepared from scrapie sick mice.
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Prions were obtained from C57Bl6 mice affected by scrapie disease produced by inoculation
with the RML prion strain. Brain containing prions were homogenized at a 1.5% in PBS
plus Complete™ cocktail of protease inhibitors (Boehringer Mannheim, Mannheim,
Germany). As controls, age matched wild type (WT) mice (littermates) were i.p. inoculated
with the same stock of prions. For second infectivity passage, 11 weeks-old C57Bl6 mice
were inoculated with brain homogenates preparations from Tg2576 mice of the 365 days old
inoculated group, showing the clinical signs of scrapie. Animals were checked three times
every week in order to evaluate health condition and appearance of scrapie clinical
symptoms. The onset of clinical prion disease was measured by scoring the animals twice a
week using the following scale: 1, Normal animal; 2, rough coat on limbs; 3, extensive
rough coat, hunchback and visible motor abnormalities; 4, uro-genital lesions; 5, terminal
stage of the disease in which the animal present cachexia and lies in the cage with little
movement. Animals scoring level 5 were considered sick and were sacrificed to avoid
excessive pain using exposition to carbonic dioxide. Left brain hemispheres were extracted
and analyzed histologically (see below). The right cerebral hemisphere was frozen and
stored at −70°C for biochemical studies. For time course PrPSc accumulation studies, 365
days old C57Bl6 mice were i.p. inoculated with the same stock of prions mentioned above
(RML from WT C57Bl6 mice). Mice were sacrificed at 140, 153, 161, 169, 181 and 193
days post inoculation (d.p.i.).
PrPSc detection
10% brain homogenates were prepared as previously described (Castilla et al., 2005). Brain
homogenates aliquots were digested with 50 μg/mL of proteinase K (PK) (Fisher
BioReagents, Fair Lawn, NJ) at 37°C for 1h and the reaction was stopped by adding
NuPAGE LDS Sample buffer (Invitrogen, Carlsbad, CA). Proteins were then fractionated by
electrophoresis using 4–12 % sodium dodecyl sulphate-polyacrylamide gels (SDS-PAGE)
(Invitrogen, Carlsbad, CA), electroblotted into Hybond-ECL nitrocellulose membrane
(Amersham Biosciences, UK) and probed with the 6H4 antibody (Prionics AG, Zurich,
Switzerland) (dilution 1:5,000). The immunoreactive bands were visualized by ECL Plus
Western blotting detection system (GE Healthcare, UK) using a UVP Bioimaging system
EC3 apparatus (UVP, Upland, CA).
Histopathological studies
Brain samples were fixed in 10% formaldehyde solution, embedded in paraffin and cut in
sections. 6μm thick serial sections from each block were stained with hematoxylin-eosin,
thioflavin S or incubated with the anti-Aβ monoclonal antibody 4G8 (Covance, Dedham,
MA) or the glial fibrillary acidic protein (GFAP) antibody (Dako Cytomation, Carpinteria,
CA), using previously described protocols (Castilla et al., 2005; Permanne et al., 2002).
Immunoreactions were developed using the peroxidase-antiperoxidase method, following
manufacturer’s specifications. Antibody specificity was verified by absorption. Samples
were visualized with a Nikon Eclipse 800 microscope. For co-immunolocalization, slides
were incubated with fluorescently labeled 4G8 and 6H4 antibodies and visualized in a Leyca
microscope. The vacuolation profile was estimated by considering both number and size of
vacuoles. Each analyzed brain area was scored from 0 to 4 according to the extent of
vacuolation in slides stained with haematoxilin-eosin and visualized at a 40X magnification,
as previously described (Castilla et al., 2005). The area and number of Aβ plaques was
assessed in cortex images of Tg2576 mice either inoculated or non-inoculated with prions.
Several images were taken from each animal using a Nikon Eclipse 800 microscope (100X
magnification). Five zones of the cortex were submitted to image analysis using
Methamorph.
Morales et al. Page 3
J Neurosci. Author manuscript; available in PMC 2010 September 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Co-immunoprecipation studies
To evaluate whether Aβ and PrP may interact in the brain we performed co-
immunoprecipitation studies from frozen brain samples. For these studies we used magnetic
beads (Dynabeads® from Invitrogen) covalently coupled with affinity purified sheep anti-
mouse polyclonal antibodies raised against mouse IgG. The monoclonal 4G8 antibody,
recognizing specifically Aβ, was bound to the beads using the manufacturer specifications.
Beads were incubated with 1% brain homogenates prepared in PBS for 60 min at 4°C with
stirring. Thereafter, the liquid solution was removed and beads washed 3 times with PBS.
Finally, beads were resuspended directly in electrophoresis sample buffer, boiled and the
solution subjected to SDS-PAGE. The gel was transferred onto nitrocellulose and the
membrane developed with the anti-PrP antibody 6D11 or the control anti-AKT antibody.
In vitro Aβ seeding assay
PrPSc was highly purified from the brains of scrapie affected animals produced by
inoculation with RML prions, using previously described protocols (Hetz et al., 2003).
Aβ1-42 peptide was synthesized using solid phase chemistry by the protein core at Yale
University. Synthetic Aβ1-42 was resuspended in acetonitrile (50% v/v), aliquoted and
lyophilized. Aliquots were resuspended in NaOH, pH 12 and filtrated using 30,000 KDa cut-
off filters (Millipore, MA). Filtrates containing soluble, seed-free Aβ were stored at −80°C
until use. The formation of Aβ aggregates was quantified by a modified sedimentation assay
previously described (Soto et al., 1995). Briefly, Aβ samples were incubated with different
amounts of PrPSc. After incubation for different times at 25°C, samples were centrifuged at
14,000 rpm for 10 min and the soluble peptide was quantified by ELISA, using 4G8
monoclonal antibody.
Full length recPrP expression and purification
Murine prnp gene (coding residues 23–230) was PCR-amplified from mouse blood using
standard molecular biology techniques. The amplicon was inserted in a pET303/CT His
vector (Invitrogen®) and propagated in DH10B-T1R E. coli cells (Invitrogen®). The plasmid
was purified and then transformed into BL21-Star E. coli cells (Invitrogen®). For
expression, freshly transformed cells were grown in 5 mL of TB medium supplemented with
kanamicin (100 ug/mL) at 37°C for 6 h. The starter culture was then diluted into 50 mL of
the same medium and grown for another 6 h. This culture was finally diluted into 750 mL of
the same medium and grown until it reached 0.7 OD. 1 mM IPTG was then added and the
cells were induced for 5 h. The culture was harvested by centrifugation and stored at −80°C.
For purification, cell pellets were thawed and resuspended in buffer A (50 mM Tris-HCl pH
8.0, 1 mM EDTA and 100 mM NaCl). Cells were lysed by adding 0.5 mg/mL Lysozyme
and subsequently sonicated. The released inclusion bodies were pelleted by centrifugation at
22,000g and then washed twice with buffer A supplemented with 0.05% (v/v) Triton X-100.
The inclusion bodies containing recPrP were solubilized for 2 h with buffer B (10 mM Tris-
HCl, 100 mM Na2HPO4 pH 8.0, 100 mM NaCl, 10 mM B-Mercaptoethanol, 6M GdnCl)
and then purified by using standard IMAC procedure. Briefly, the sample was bound to Ni
Sepharose 6 Fast Flow resin (GE Healthcare®) in batch-mode for 1 h at RT and then washed
with buffer B. Recombinant PrPC was on-column refolded for 6 h and eluted with 500 mM
Imidazole. The main peak was collected and quickly filtered to remove aggregates. The
sample was buffer-exchanged using Zeba-desalting columns (Pierce®), further concentrated
to ~0.5 mg/mL and flash-frozen at −80°C. Protein inhibitors (Complete Protease Inhibitor
Cocktail from Roche®) were used throughout the purification to minimize degradation. The
protein was confirmed to be monomeric and folded by SDS-PAGE, Western blotting and
Circular Dichroism.
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Seeding of recPrP with Aβ fibrils
Pure recPrP was incubated with Aβ fibrils following a modified protocol from a previously
reported procedure for in vitro PrP conversion (Atarashi et al., 2008). 4.3 μM recPrP (10 μg
of protein) was mixed with pre-formed Aβ fibrils (fibrillogenesis was confirmed by
thioflavin T assay and electron microscopy) at different recPrP/Aβ fibrils ratios in
conversion buffer (0.4 % SDS, 0.4 % TritonX-100, 1X PBS). The mixture was incubated for
30 h at 37°C in an Eppendorf® Thermomixer with cycles of 1 minute agitation at 1500 rpm
and 1 minute incubation. For analysis, samples were treated with 7 μg/mL of PK and
incubated at 37°C for one hour in a water bath. The reaction was stopped by quickly adding
SDS sample buffer and heating at 95°C for 10 min. Samples were analyzed by Western
blotting using 6D11 anti-PrP antibody.
Statistical analysis
Survival curves, in vitro Aβ seeding assay, profile of spongiform degeneration and Aβ
plaque quantifications were analyzed by GraphPad Prism version 5.0 software (GraphPad
Software, La Jolla, CA).
Results
In order to assess the in vivo interaction between the pathological processes implicated in
AD and TSEs, we inoculated prions intra-peritoneally (i.p.) into Tg2576 mice at different
stages of AD progression. One group of animals was inoculated at 45 days old when Aβ
accumulation is not yet detectable and a second group was inoculated at the age in which
amyloid deposition begin in these animals (365 days old). Age-matched wild type mice
(non-transgenic littermates) were treated in the same way. Evaluation of the onset of prion
disease showed that Tg2576 mice develop clinical symptoms significantly faster than WT
littermates (Fig. 1). Interestingly, the acceleration of the disease depended on the stage of
AD-like pathology, since transgenic mice inoculated at 365 days old showed a substantially
shorter incubation period than animals inoculated at 45 days old (Fig. 1). These differences
are not an effect of the animal age, because WT mice inoculated at 45 or 365 days old did
not show any statistically significant difference in the onset of prion symptoms. To assess
whether the accelerated disease produced in Tg2576 animals kept the infectious
characteristics, we inoculated WT mice with brain homogenate of sick animals from the
group of Tg2576 injected at 365 days old. The results of this second passage showed an
average incubation period of 202.4 days, characteristic of RML prions inoculated i.p. and
similar to the incubation time observed in our first passage in WT animals (Fig. 1).
Additional biochemical (glycosylation profile and electrophoretical mobility of PrPSc) and
pathological (spongiform degeneration and astroglyosis) studies further showed that the
RML-Tg2576 properties were the same as expected for RML prions (supplementary figure
1). These results indicate that the strain characteristics of RML prions are likely maintained
after passage in AD transgenic mice.
Histopathological analyses of brains from Tg2576 prion infected mice showed the
coexistence of both TSE and AD pathologies. The brain exhibited extensive spongiform
degeneration (Fig. 2A), reactive astrogliosis (Fig. 2B), Aβ deposition (Fig. 2C and 2D) and
PrPSc accumulation (see Fig. 4 below). Conversely, Aβ deposits were not detected in the
brains of WT mice inoculated with prions and no vacuolation or PrPSc accumulation was
seen in old non-infected Tg2576 mice (Fig. 2).
The degree of spongiform degeneration in animals with the double pathology did not differ
from those affected only by TSE (Fig 2A). The extent of vacuolation in diverse areas of the
brain is widely used to characterize TSEs. Indeed, different prion strains often produce a
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distinct pattern of spongiform degeneration (Morales et al., 2007). Evaluation of the lesion
profile in different brain areas of Tg2576 mice infected with prions showed a similar pattern
in all inoculated groups (Supplementary Fig. 2). Vacuolation profiles were not statistically
significantly different between Tg2576 and WT prion infected mice, indicating that
spongiform degeneration did not change due to the presence of Aβ deposits.
Conversely, it is clear that both brain inflammation (Fig. 2B) and Aβ deposition (Fig. 2C
and 2D) were substantially higher on animals bearing the double pathology. The increase on
brain inflammation may be an additive result, since both pathologies are associated with
astrogliosis (Diedrich et al., 1987) (Fig. 2B). More remarkably is the dramatic increase on
Aβ deposition observed in the Tg2576 inoculated mice compared with non-infected animals.
Indeed, some of the Tg2576 mice (2 out of 8) inoculated at 45 days old and sacrificed when
prion disease was evident (around 185 days later), showed Aβ diffuse amyloid deposits at an
age (~230 days) when these animals never show amyloid lesions (Fig. 2C). These deposits
were recognized with anti-Aβ specific antibodies in both hippocampus and cortex (Fig. 2C),
but were negative for thioflavin S (Fig 2D). The later is not surprising since early, diffuse,
pre-amyloid deposits in Alzheimer’s brain are usually not detectable by this amyloid-
binding die (Tagliavini et al., 1998). However, a more detailed study of thioflavin S staining
at higher magnification showed that these lesions were indeed slightly stained by thioflavin
S (Supplementary Fig 3). Moreover, the size, number and maturity of Aβ plaques in the
Tg2576 group inoculated at 365 days old was dramatically higher than in the age-matched
control inoculated with PBS (Fig. 2C). To quantitatively analyze the extent of Aβ
aggregation in prion infected Tg2576 mice, we determined both the percentage of brain area
covered by thioflavin S positive Aβ aggregates and the number of plaques between 365 days
old prion infected and age-matched non-infected animals. The results showed that Aβ plaque
area as well as the number of plaques was significantly higher in Tg2576 mice infected with
prions (P<0.01). Indeed, infected animals have more than 2-fold higher number of plaques
and strikingly more than 10-fold greater plaque area than non-infected Tg2576 (data not
shown). These data strongly supports an interaction between the prion and AD pathologies,
leading to a dramatic increase on the misfolding, aggregation and cerebral accumulation of
Aβ in the presence of PrPSc.
To evaluate whether PrPSc accumulation was also increased in the presence of AD
pathology, we measured the quantity of PrPSc in the brain by Western blot analysis (Fig. 3).
Infected Tg2576 mice were sacrificed when clinical signs of scrapie were confirmed, in
average 186 and 165 days post-inoculation (d.p.i.) in animals injected at 45 and 365 days
old, respectively. As shown in figure 3A, the quantity of PrPSc in the brain was high and
similar in these two groups (one representative animal is shown in each group). No PrPSc
was detected in AD transgenic mice non-infected with prions. As comparison we analyzed
by Western blot the levels of PrPSc in 365 days old prion inoculated WT mice at different
time points after i.p. inoculation (Fig. 3B and supplementary table 1). In animals sacrificed
at 140, 153 and 161 d.p.i. no PrPSc was detected even in concentrated samples (Fig. 3C). In
contrast, at these times most of the Tg2576 mice inoculated at 365 days old showed clear
clinical signs and strong deposition of PrPSc in their brains (Fig 1 and Fig 3A, C). At 169
d.p.i. only one out of three WT mice showed a very faint PrPSc signal (in absence of clinical
signs) (Fig. 3B). The quantity of PrPSc in the brain of infected WT mice became high and
similar to the one in Tg2576 groups after around 225 days post-inoculation (Fig. 3B and C).
These results indicate that PrPSc formation and accumulation in the brain is accelerated in
mice simultaneously affected by AD brain pathology.
One putative explanation for the acceleration of AD and TSE pathologies in animals
affected by both diseases could be a direct interaction between Aβ and PrP misfolded
proteins leading to speeding up the process of misfolding and aggregation. To assess this
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possibility, we studied the colocalization of both proteins in pathological aggregates. In
Tg2576 mice injected with prions at 365 days old we detected signals reactive against Aβ
and PrP antibodies in both compacted amyloid plaques, typical of AD, and large diffuse
deposits, characteristics of prion affected animals (Fig. 4A). Conversely, no colocalization
was observed in non-infected Tg2576 or WT infected with RML, where only the
characteristics aggregates associated to AD or prion disease were observed, respectively
(Fig. 4A). These results suggest that misfolded proteins interact in the brain when both
pathological processes are occurring simultaneously. To further assess the interaction
between Aβ and PrP in the brain we performed co-immunoprecipitation studies. As shown
in figure 4B, immunoprecipitation using the 4G8 antibody that specifically recognize Aβ,
co-immunoprecipitated a large amount of PrP in T2576 animals inoculated with prions. A
fainter band was also observed in prion infected WT animals, but no signal was observed in
transgenic or WT mice non-infected with prions. A negative control developed with the
antibody against the AKT protein showed no co-immunoprecipitation (Fig. 4B).
To evaluate whether the interaction between Aβ and PrP may have functional consequences
for the processes of protein misfolding and aggregation, we performed in vitro aggregation
experiments in mixtures of both proteins. It is widely accepted that proteins misfold and
aggregate by a seeding-nucleation mechanism, in which the formation of an oligomeric
nuclei is the key step that control the kinetic of aggregation (Jarrett and Lansbury, 1993;
Soto et al., 2006). It has been described that seeds composed of one protein can accelerate a
second misfolding process through a process known as cross-seeding (Harper and Lansbury,
1997; O’Nuallain et al., 2004). To test the possibility that Aβ and PrP may cross-seed each
other to accelerate protein misfolding and aggregation, we evaluated the seeding capability
of purified PrPSc in the aggregation of synthetic Aβ (Fig. 5A). Addition of various small
quantities of prion seeds produced a clear and dramatic acceleration of Aβ aggregation,
measured as a shortening of the lag phase for polymerization. The acceleration of Aβ
aggregation was directly proportional to the quantity of PrPSc seeds added to the sample
(Fig. 5A). These results may explain in part the large increase of Aβ deposition observed in
animals inoculated with murine prions. In order to evaluate whether Aβ aggregates alter PrP
misfolding, we studied the aggregation of recombinant prion protein (recPrP) in the presence
of different quantities of Aβ fibrils. The formation of misfolded recPrP was studied by the
standard proteinase K (PK) degradation assay followed by western blot. In the absence of
Aβ fibrils, only faints bands of PK resistance recPrP were observed with molecular weights
of 17 and 12 KDa, similar to previously reported results (Atarashi et al., 2008) (Fig. 5B).
However in the presence of various quantities of Aβ aggregates, a prominent PK-resistant
band was observed with an apparent molecular weight of around 17KDa. The switch on the
molecular weight is indicative of bona-fide PrP conversion and is similar to the size
expected for the unglycosylated PK resistant PrPSc core. We are currently testing whether
misfolded recPrP produced upon incubation with Aβ fibrils is infectious to animals.
Interestingly, the extent of PK-resistant recPrP was directly proportional to the quantity of
Aβ fibrils added to the reaction (Fig. 5B). This data provides evidence for a functional
interaction between Aβ and PrP resulting in mutual acceleration of protein misfolding and
aggregation by cross-seeding.
Discussion
PMDs include more than 25 clinically diverse human disorders (Chiti and Dobson,
2006;Soto, 2001). Despite the obvious differences among these diseases, the molecular
mechanism triggering the pathology appears to be the same: the misfolding, aggregation and
tissue accumulation of a protein (Chiti and Dobson, 2006; Soto, 2001). Although the protein
involved in each disease is different, the structure of the misfolded aggregates as well as the
mechanism and intermediates in the process are similar (Glabe, 2006; Soto et al., 2006).
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Indeed, a typical signature of most PMDs is the accumulation of amyloid-like fibrils, folded
in a β-cross conformation (Sunde et al., 1997). To reach this stage, a series of events of
misfolding and protein-protein interaction occur to form oligomers and protofibrils in a
process of seeded/nucleated polymerization (Soto et al., 2006). The cellular consequences of
the accumulation of misfolded aggregates in distinct diseases are also similar and include
extensive tissue inflammation, cellular stress and activation of the unfolded-protein response
(UPR) (Rutkowski and Kaufman, 2004). The permanent accumulation of aggregates as well
as the failure of the clearance system to eliminate them, leads to chronic endoplasmic
reticulum stress, saturation of the proteasome system and activation of apoptotic pathways,
resulting in cellular dysfunction and death (Kopito, 2000; Morimoto, 2008).
The mechanistic and pathological similarities among these diseases suggest that protein
misfolding processes occurring simultaneously may synergistically interact among each
other leading to an acceleration of the disease. Indeed, it has been reported extensively the
co-existence of two PMDs in a single patient, including cases of AD, PD, TSEs, ALS,
diabetes type 2, systemic amyloidosis, etc (Brown et al., 1998; Brown et al., 1990;
Fernandez-Alonso et al., 1994; Giasson et al., 2003; Moss et al., 1988; Popescu et al., 2004;
Rajput et al., 1993). Moreover, some PMDs involve the presence of more than one type of
misfolded aggregated protein; the archetype case being AD, where intracellular
neurofibrillary tangles (NFT) composed of hyperphorylated Tau are present simultaneously
with extracellular Aβ amyloid plaques (Dickson, 2001). Although it is possible that NFT and
senile plaques are formed independently, a recent study showed that Aβ and tau form
soluble complexes that may promote their self-aggregation into the insoluble forms observed
in AD (Guo et al., 2006).
Our findings suggest that AD and TSE pathologies synergistically interact to accelerate the
onset of both diseases. Indeed, scrapie clinical signs appear much faster after infection of
animals that are simultaneously accumulating Aβ aggregates. The rate of acceleration
depended on the stage of AD and correlated with a rapid accumulation of PrPSc. On the
other hand, AD transgenic mice infected with prions developed a strikingly higher load of
cerebral amyloid plaques that appeared much faster than in non-infected mice. We cannot
completely rule out that that the increased Aβ amyloid accumulation in prion infected
animals might be due in part to an inflammatory response produced by other factors present
in the injected brain homogenate. However, we believe this is unlikely considering that a
similar result in terms of exacerbation of protein misfolding and aggregation of PrPSc was
induced by the presence of the amyloid-beta aggregates, which were produced by
transgenesis and not by injection of an exogenous substance. Furthermore, recent studies,
aimed to assess the possibility that Alzheimer’s pathology could be transmissible, showed
that inoculation of brain homogenate from humans (not affected by AD) or wild type
animals into AD transgenic mice did not produce any increase or acceleration of amyloid
deposition (Meyer-Luehmann et al., 2006).
There are at least three possible explanations for the synergistic effects observed in our
study: 1) The clearance mechanisms already impaired by one misfolded protein may be
further diminished by a second misfolding event, leading to the faster and higher
accumulation of both type of aggregates and subsequent brain damage. 2) Nerve cells
stressed and injured by exposure to one toxic misfolded aggregated protein might be more
easily damaged by an additional toxic aggregate. This would lead to accelerated and more
severe cellular dysfunction and death. 3) A direct interaction between misfolded proteins
may result in acceleration of protein misfolding and aggregation through a cross-seeding
mechanism, leading to higher and faster accumulation of toxic aggregates. The latter
possibility is supported by our co-immunolocalization and co-immunoprecipitation studies
which provide evidence for a direct interaction between Aβ and PrP in the brain. This idea is
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further supported by our in vitro experiments in which purified PrPSc can accelerate
aggregation of synthetic Aβ and preformed Aβ aggregates can induce the formation of
misfolded protease-resistance PrPSc-like. Therefore, our findings lend support for the
possibility of a direct interaction between the proteins leading to cross-seeding and increased
pathogenesis. Several studies have demonstrated the cross-seeding of misfolded aggregates
both in vitro and in vivo (Johan et al., 1998;O’Nuallain et al., 2004). These data added to the
now well-accepted idea that seeding is the general mechanism by which these proteins
aggregate and the basis for disease propagation in TSEs (Soto et al., 2006), determine that
cross-seeding between diverse misfolded proteins is a feasible mechanism. However, given
the complexity of the signaling events and changes produced in the disease brain it cannot
be ruled out that other pathways also contribute to explain the effects observed in our
experiments. Furthermore, two recent and interesting reports indicating that PrPC may be
involved in regulating the β-secretase cleavage of APP to produce Aβ (Parkin et al., 2007)
or act as a receptor for Aβ oligomers in cells (Lauren et al., 2009). These studies provide
additional pathways by which these diseases may interact at the molecular level.
Regardless of which is the molecular mechanism explaining the acceleration and
exacerbation of AD and TSEs pathologies in animals affected by both diseases, our results
suggest that one PMD is a significant risk factor for the emergence of a second disease.
Whether this conclusion can be extrapolated to the diseases in humans will require
additional epidemiological studies. In this sense, it is important to highlight that it has
already been shown that the two most prevalent PMDs (AD and diabetes type 2) are a risk
factor for each other (Arvanitakis et al., 2004; Janson et al., 2004). In the case of AD and
TSEs, it would be important to study whether the rare, but infectious prion diseases may
contribute to increase the risk for AD in patients infected with prions. Since human TSEs
have a very long incubation period, which can span several decades (Collinge et al., 2006), it
can be speculated that people infected with prions may develop AD or other PMDs before
showing the symptoms of prion disease, contributing to explain the low incidence of TSEs
in humans. Therefore, our findings may have profound implications to understand the origin
and progression of human disorders associated with the misfolding and aggregation of
proteins.
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Figure 1. Alzheimer’s pathology accelerates prion disease in mice models
A: To assess the effect of AD neuropathology in the onset of prion disease we inoculated i.p.
Tg2576 mice with RML prions at 365 (red line) and 45 (green line) days old. As control, age
matched WT mice (non-transgenic littermates) were inoculated with the same stock and
quantity of the infectious agent (black line). WT animals infected at 45 or 365 days old
developed prion disease at very similar times and thus the data for these two groups are
presented together in the graph. Clinical signs were assessed as described in Methods. When
animals were definitively diagnosed with prion disease they were sacrificed to avoid further
pain. The data show that both groups of Tg2576 inoculated mice develop prion disease at a
shorter time compared to age matched WT controls. In addition, we performed a second
infectivity passage in WT mice by inoculating infectious material from the brain of a sick
Tg2576 animal injected at 365 days old (blue line). B: Average of incubation periods of the
different groups showed in panel A, including the statistical comparison between each
experimental group with the WT control mice. The statistical analysis was done using the
student-t test.
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Figure 2. Brain histopathological studies
Representative animals from different groups were studied histopathologically for
spongiform brain degeneration after hematoxilin-eosin staining (A), reactive astroglyosis by
GFAP staining (B) and Aβ deposition by immunohistochemistry using the 4G8 anti-Aβ
antibody (C) and staining with the amyloid specific die thioflavin S (D). It is important to
emphasize that the prion deposits in mice affected by RML prions are not thioflavin S
positive, but are rather diffuse pre-fibrillar aggregates. The pictures in panel A and B
correspond to the medulla, panel C to the hippocampus or cortex as indicated, and panel D
to the cortex. (See also supplementary figures 2 and 3).
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Figure 3. PrPSc levels in Tg2576 or WT mice inoculated with prions
A: Brain homogenates from clinically sick Tg2576 mice inoculated with prions at 45 or 365
days old or as a control Tg2576 mice non-inoculated with prions (right panel) were PK
digested and Western blotted in order to analyze PrPSc burden. The result shown
corresponds to one animal representative of all mice in the group. The animal of the 45 days
group shown in the figure was sacrificed at 190 days post-inoculation (dpi) and the animal
of the 365 days at 159 dpi. B: For comparison, we measured the PrPSc levels in the brain of
WT mice challenged with RML prions and sacrificed at 140, 169, 193 and 225 dpi. Only the
animal at 225 dpi was exhibiting signs of prion disease. Numbers at the top of each gel
represent brain dilution. Brain dilutions were performed from a 10% brain homogenates and
various dilutions are shown to facilitate the comparisons. C: Densitometric analysis of PrPSc
quantity in different animals. Western blot data as those shown in panels A and B were
evaluated densitometrically to estimate the extent of the PrPSc signal. The data represent the
average and standard error of 5 different animals in each group. As seen, Tg2576 mice
inoculated with prions at 45 and 365 days old accumulate a similar quantity of PrPSc as WT
mice but at a much shorter time. (See also Supplementary Table 1).
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Figure 4. Interaction between Aβ and PrP in the brain
A: Sections from the cortex of animals in different groups were stained with fluorescent
antibodies against Aβ (4G8, green) and PrP (6H4, red) and co-localization evaluated by
confocal microscopy. White arrows point to the typical Aβ amyloid plaques seen in
transgenic mice and AD patients; yellow arrows point to the typical diffuse accumulations of
PrPSc aggregates in the brain of TSE affected individuals. B: Co-immunoprecipitation
experiments. Aliquots from the brain of animals from different groups were
immunoprecipitated by 4G8 antibody, which specifically recognize Aβ. The
immunoprecipitated material was separated by electrophoresis and analyzed by western blot
using the 6H4 anti-prion antibody and as control the AKT antibody.
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Figure 5. Cross-seeding of PrP and Aβ misfolding and aggregation in vitro
A: The effect of purified PrPSc on Aβ aggregation was measured overtime by sedimentation
followed by sensitive ELISA. Seed-free soluble Aβ1-42 (0.01 mg/ml) was incubated with
different concentrations of purified PrPSc seeds or PBS (control). The concentration of PrPSc
is expressed as a percentage of oligomers per Aβ monomer and was calculated assuming
that a PrPSc oligomer has an average molecular weight of 7,700 KDa. The latter was based
on data coming from flow field fractionation of PrPSc and corresponds to the fraction with
the highest concentration of PrPSc (Silveira et al., 2005). Samples were incubated at 25°C
with shaking for the indicated times. Thereafter soluble and aggregated Aβ were separated
by centrifugation at 14,000 rpm for 10 min and the quantity of peptide in the supernatant
was measured by ELISA. Experiment was done by triplicate and results represent the
average ± standard error. Analysis by two-ways ANOVA (using condition and time as the
variables) show that the kinetic of Aβ aggregation in the presence of PrPSc is highly
significantly different from the control (P<0.0001). B: The effect of Aβ aggregates on PrP
misfolding was studied by incubating 10 μg of recombinant mouse PrP in the presence of
increasing concentrations of preformed Aβ fibrils. Fibrils were prepared as indicated in
Methods and aliquots corresponding to 0.14% (1.2 μg of total Aβ), 0.28% (2.4 μg of total
Aβ), 0.56% (4.8 μg of total Aβ) and 1.1% (9.6 μg of total Aβ) were added to monomeric
recPrP (lines 1, 2, 3, and 4 respectively). The concentration of Aβ fibrils is expressed as a
molar percentage per recPrP monomer and was calculated assuming that the average
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molecular weight of Aβ fibrils is 2,000 KDa, as estimated by a combination of size-
exclusion chromatography, atomic force microscopy and electron microscopy (Goldsbury et
al., 2000). The mixture was incubated for 30 h at 37°C in an Eppendorf® Thermomixer with
cycles of 1 minute agitation at 1500 rpm and 1 minute incubation. To assess PrP misfolding,
samples were incubated at 37°C with 7 ug/mL of PK and PrPres signal analyzed by western
blot. Line 5 is the control with the same quantity of recPrP incubated in the absence of Aβ
fibrils. Line 6 corresponds to recPrP non-treated with PK to display the migration of the full
length protein. The numbers at the right side correspond to the molecular weight standards.
Morales et al. Page 18
J Neurosci. Author manuscript; available in PMC 2010 September 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
